Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy?;Impact de la prise de statines sur les groupes à risques de progression de D'Amico et la survie sans récidive biologique après prostatectomie totale

Progres en Urologie

Volumn 22, Issue 5, 2012, Pages 273-278

  Misrai, V ^a   Do, C ^b   Lhez, J M ^a   Elman, B ^a   Latorzeff, I ^a   Portalez, D ^a   Grosclaude, P ^b  

^a CLINIQUE PASTEUR   (France)

^b INSERM   (France)

Author keywords

Prostate cancer; Radical prostatectomy; Statin; Survival

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUMOR RECURRENCE;

AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84859816359     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2011.11.001     Document Type: Article

References (28)

1. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
2. Freeman M.R., Solomon K.R. Cholesterol and prostate cancer. J Cell Biochem 2004, 91:54-69.
3. Homma Y., Kondo Y., Kaneko M., Kitamura T., Nyou W.T., Yanagisawa M., et al. Promotion of carcinogenesis and oxidative stress by dietary cholesterol in rat prostate. Carcinogenesis 2004, 25:1011-1014.
4. Dobs A.S., Schrott H., Davidson M.H., Bays H., Stein E.A., Kush D., et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metab Clin Exp 2000, 49:1234-1238.
5. Hamilton R.J., Freedland S.J. Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol. 2008, 18:333-339.
6. Graaf M.R., Beiderbeck A.B., Egberts A.C.G., Richel D.J., Guchelaar H.J. The risk of cancer in users of statins. J Clin Oncol 2004, 22:2388-2394.
7. Shannon J., Tewoderos S., Garzotto M., Beer T.M., Derenick R., Palma A., et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005, 162:318-325.
8. Ford I., Murray H., Packard C.J., Shepherd J., Macfarlane P.W., Cobbe S.M. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007, 357:1477-1486.
9. Lovastatin Study Groups I through IV Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993, 153:1079-1087.
10. Kaye J.A., Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004, 90:635-637.
11. Browning D.R.L., Martin R.M. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007, 120:833-843.
12. Hamilton R.J., Goldberg K.C., Platz E.A., Freedland S.J. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008, 100:1511-1518.
13. Krane L.S., Kaul S.A., Stricker H.J., Peabody J.O., Menon M., Agarwal P.K. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 2010, 183:118-124.
14. Mondul A.M., Han M., Humphreys E.B., Meinhold C.L., Walsh P.C., Platz E.A. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011, 185:1268-1273.
15. Hamilton R.J., Banez L.L., Aronson W.J., Terris M.K., Platz E.A., Kane C.J., et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010, 116:3389-3398.
16. Ritch C.R., Hruby G., Badani K.K., Benson M.C., McKiernan J.M. Effect of statin use on biochemical outcome following radical prostatectomy. BJU 2011, Available from: http://www.ncbi.nlm.nih.gov/pubmed/21453350.
17. Endo A., Kuroda M., Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot 1976, 29:1346-1348.
18. Friis S., Poulsen A.H., Johnsen S.P., McLaughlin J.K., Fryzek J.P., Dalton S.O., et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005, 114:643-647.
19. Blais L., Desgagngagn Johnsen S.P., McLaughlin J.K., Fryzek J.P., Dalton S.O., et al. Cancer risk among statin users: a population-based cohort study. Int Arch Intern Med 2000, 160:2363-2368.
20. Yokomizo A., Shiota M., Kashiwagi E., Kuroiwa K., Tatsugami K., Inokuchi J., et al. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. Prostate. 2011, 71:298-304.
21. Wright J.L., Lin D.W., Stanford J.L. The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate 2011, Available from: http://www.ncbi.nlm.nih.gov/pubmed/21432865.
22. Wu C., Moreira D.M., Gerber L., Rittmaster R.S., Andriole G.L., Freedland S.J. Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 2011, Available from: http://www.ncbi.nlm.nih.gov/pubmed/21709690.
23. Hong S.K., Oh J.J., Byun S.-S., Hwang S.I., Lee H.J., Choe G., et al. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥12)-core biopsy. Prostate 2011, Available from: http://www.ncbi.nlm.nih.gov/pubmed/2ww.ncbi.nlm.nih.gov/pubmed/21520162.
24. Murtola T. Editorial comment. J Urol 2010, 184(2):500.
25. Tan N., Klein E.A., Li J., Moussa A.S., Jones J.S. Statin use and risk of prostate cancer in a population of men who underwent biopsy. J Urol 2011, 186:86-90.
26. Loeb S., Kan D., Helfand B.T., Nadler R.B., Catalona W.J. Is statin use associated with prostate cancer aggressiveness?. BJU Int. 2010, 105:1222-1225.
27. Ouzzane A., Koenig P., Ballereau C., Zini L., Ghoneim T., Maladry F., et al. Oncologic outcomes after radical prostatectomy: French validation of the D'Amico risk group classification. Prog Urol. 2010, 20:1206-1212.
28. Goldstein M.R., Mascitelli L., Pezzetta F. How statins may increase prostate cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:459.